Distribution of MRI-derived T2 values as a biomarker for in vivo rapid screening of phenotype severity in mdx mice
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310551 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Emily A Waters und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chemistry of Life Processes Institute and Biomedical Engineering, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of …. Hauptthemen laut MEDLINE: Mice, Inbred mdx, Magnetic Resonance Imaging, Muscular Dystrophy, Duchenne, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, Lakeside Discovery, NCI.
Abstract (Originalsprache)
Background
The pathology in Duchenne muscular dystrophy (DMD) is characterized by degenerating muscle fibers, inflammation, fibro-fatty infiltrate, and edema, and these pathological processes replace normal healthy muscle tissue. The mdx mouse model is one of the most commonly used preclinical models to study DMD. Mounting evidence has emerged illustrating that muscle disease progression varies considerably in mdx mice, with inter-animal differences as well as intra-muscular differences in pathology in individual mdx mice. This variation is important to consider when conducting assessments of drug efficacy and in longitudinal studies. We developed a magnetic resonance imaging (MRI) segmentation and analysis pipeline to rapidly and non-invasively measure the severity of muscle disease in mdx mice.
Methods
Wildtype and mdx mice were imaged with MRI and T2 maps were obtained axially across the hindlimbs. A neural network was trained to rapidly and semi-automatically segment the muscle tissue, and the distribution of resulting T2 values was analyzed. Interdecile range and Pearson Skew were identified as biomarkers to quickly and accurately estimate muscle disease severity in mice.
Results
The semiautomated segmentation tool reduced image processing time approximately tenfold. Measures of Pearson skew and interdecile range based on that segmentation were repeatable and reflected muscle disease severity in healthy wildtype and diseased mdx mice based on both qualitative observation of images and correlation with Evans blue dye uptake.
Conclusion
Use of this rapid, non-invasive, semi-automated MR image segmentation and analysis pipeline has the potential to transform preclinical studies, allowing for pre-screening of dystrophic mice prior to study enrollment to ensure more uniform muscle disease pathology across treatment groups, improving study outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemistry of Life Processes Institute and Biomedical Engineering, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
ORCID-Profile: Alexis R Demonbreun
Förderung
- NIH
- Lakeside Discovery
- NCI
- Chan Zuckerberg Initiative DAF
Zitieren
APA
Waters, E. A., Haney, C. R., Vaught, L. A., McNally, E. M., & Demonbreun, A. R. (2024). Distribution of MRI-derived T2 values as a biomarker for in vivo rapid screening of phenotype severity in mdx mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0310551
Vancouver
Waters EA, Haney CR, Vaught LA, McNally EM, Demonbreun AR. Distribution of MRI-derived T2 values as a biomarker for in vivo rapid screening of phenotype severity in mdx mice. PLOS ONE. 2024. doi:10.1371/journal.pone.0310551
BibTeX
@article{Waters2024,
author = {Waters, Emily A and Haney, Chad R and Vaught, Lauren A and McNally, Elizabeth M and Demonbreun, Alexis R},
title = {Distribution of MRI-derived T2 values as a biomarker for in vivo rapid screening of phenotype severity in mdx mice},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310551}
}
EUVIMED